Cue Biopharma

iCAD (NASDAQ: ICAD) Stock Quote

Follow Insider Trades Visit website
Last Trade: US$1.30 0.05 4.00
Volume: 94,046
5-Day Change: -2.99%
YTD Change: -28.96%
Market Cap: US$33.080M

Latest News From iCAD

May 18, 2023
iCAD’s ProFound AI Breast Suite Wins U.S. General Services Administration’s AI Healthcare Challenge Award
NASHUA, N.H., May 18, 2023 (GLOBE NEWSWIRE) -- iCAD, Inc . (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced its ProFound AI ® Breast Suite is a winner of the U.S. General Services Administration’s (GSA) “AI Healthcare Challenge” award. iCAD presented its portfolio of breast cancer detection, density assessment and risk evaluation solutions at the... Read More
May 15, 2023
iCAD Reports Financial Results for First Quarter Ended March 31, 2023
NASHUA, N.H., May 15, 2023 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today reported its financial and operating results for the three months ended March 31, 2023. Highlights: ● Body of evidence supporting iCAD’s technologies grows, with compelling new research supporting Company’s Breast AI Suite and Xoft presented at key... Read More
May 11, 2023
iCAD: New Long-Term Real-World Research Confirms Xoft Skin eBx is as Safe and Effective as Mohs Surgery
NASHUA, N.H., May 11, 2023 (GLOBE NEWSWIRE) -- iCAD, Inc . (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced compelling new long-term real-world research confirms Xoft Skin eBx is as safe and effective as Mohs surgery for the treatment of non-melanoma skin cancer (NMSC). In the longest-term study of Xoft Skin eBx to-date, published in the Journal... Read More
May 3, 2023
iCAD Showcases Breast AI Suite at Society of Breast Imaging Symposium, World’s Largest Breast Imaging Conference
NASHUA, N.H., May 03, 2023 (GLOBE NEWSWIRE) -- iCAD, Inc . (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced it will showcase its Breast AI Suite of cancer detection, density assessment and risk evaluation solutions at the world’s largest breast imaging conference, the Society of Breast Imaging (SBI) Symposium, taking place May 4-7 in National... Read More
May 1, 2023
iCAD to Report First Quarter 2023 Financial Results on May 15, 2023
NASHUA, N.H., May 01, 2023 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced that it will release financial results for the first quarter ended March 31, 2023, after the market close, and host a conference call at 4:30 PM Eastern Time on Monday, May 15, 2023. Earnings call details are as follows: Domestic:... Read More
April 25, 2023
iCAD’s “ProFound Insights, ProFound Impact” Webinar Series to Feature Boca Raton Regional Hospital
NASHUA, N.H., April 25, 2023 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced its “ProFound Insights, ProFound Impact” webinar series will feature Kathy Schilling, MD, Medical Director, Christine E. Lynn Women's Health & Wellness Institute, Boca Raton Regional Hospital. The live event, titled “Elevating Accuracy... Read More
April 20, 2023
iCAD: New and Real-World Clinical Evidence Confirms ProFound AI Increases Cancer Detection without Increasing the Rate of Recalls and Reveals Critical Clues to Inform Clinical Decisions
NASHUA, N.H., April 20, 2023 (GLOBE NEWSWIRE) -- iCAD, Inc . (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced new real-world research confirms ProFound AI ® has been proven to increase cancer detection rates and provide vital clues for breast imagers' clinical decisions through two studies. One study demonstrated that ProFound AI improved... Read More
April 17, 2023
iCAD Strengthens Leadership Team with Appointment of Chief Financial Officer and New Senior Executives
NASHUA, N.H., April 17, 2023 (GLOBE NEWSWIRE) -- iCAD, Inc . (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced the Board of Directors has approved the appointment of Eric Lonnqvist as Chief Financial Officer (CFO), effective immediately, as well as Vasu Avadhanula as Chief Product Officer (CPO) and Michelle Strong as Chief Operations Officer (COO),... Read More
April 4, 2023
iCAD: ProFound AI Risk Outperforms Traditional, Widely-Accepted Breast Cancer Risk Models for Both Short-term and Long-term Risk Assessments
NASHUA, N.H., April 04, 2023 (GLOBE NEWSWIRE) -- iCAD, Inc . (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced new clinical evidence published in the Journal of Clinical Oncology found ProFound AI® Risk for 2D Mammography is more accurate than Tyrer-Cuzick v8, a commonly used lifestyle risk model, for both short-term and long-term risk assessments.... Read More
March 28, 2023
iCAD Reports Financial Results for Fourth Quarter ended December 31, 2022 and Year End
Strategy focused on profitability by end of 2024, using current cash on hand New leadership to host conference call and webcast today at 4:30 PM ET NASHUA, N.H., March 28, 2023 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today reported its financial and operating results for the twelve months ended December 31, 2022.... Read More
March 23, 2023
iCAD’s Breast AI Suite Empowers Customers to Lead the Way in Support of FDA’s National Breast Density Reporting Standard
NASHUA, N.H., March 23, 2023 (GLOBE NEWSWIRE) -- iCAD, Inc . (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced its technologies are empowering customers to lead the way in breast care, while supporting the national breast density reporting standard recently established by the U.S. Food and Drug Administration (FDA). The Company will be showcasing... Read More
March 13, 2023
iCAD Previews Fourth Quarter Financial Results, Full Report on March 28, 2023
NASHUA, N.H., March 13, 2023 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced that it will release financial results for the fourth quarter and year ended December 31, 2022, after the market close, and host a conference call at 4:30 PM ET on Tuesday, March 28, 2023. Based on preliminary, unaudited financial... Read More
March 13, 2023
iCAD Announces Leadership Transition
Stacey Stevens Resigns as President and CEO and as a Member of the Board Dana Brown Named President and CEO, remains Chairman of the Board NASHUA, N.H., March 13, 2023 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced the Board of Directors has accepted the resignation, for personal reasons, of Stacey Stevens as... Read More
March 1, 2023
iCAD: New Real-World Clinical Evidence Confirms ProFound AI Boosts Radiologists’ Efficiency and Accuracy
NASHUA, N.H., March 01, 2023 (GLOBE NEWSWIRE) -- iCAD, Inc . (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced new real-world clinical evidence to be presented at the European Congress of Radiology (ECR) 2023 meeting confirms ProFound AI® boosts radiologists’ efficiency and accuracy. The Company is also showcasing its Breast AI Suite of... Read More
February 9, 2023
iCAD to Participate in the BTIG Snowbird MedTech, Digital Health, Life Science and Diagnostic Tools Conference
NASHUA, N.H., Feb. 09, 2023 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced the Company will participate in the BTIG Snowbird MedTech, Digital Health, Life Science & Diagnostic Tools Conference from February 14-16, 2023 in Snowbird, UT. Stacey Stevens, President and CEO of iCAD, Inc., will participate in one-on-one... Read More
January 23, 2023
iCAD Announces CFO Transition and Hires New Senior Vice President, US Commercial Sales, AI
Daniel Shea appointed as interim Chief Financial Officer William Keyes hired as Senior Vice President, US Commercial Sales, AI NASHUA, N.H., Jan. 23, 2023 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced the Board of Directors has approved the appointment of Daniel Shea, CPA, as interim Chief Financial Officer (CFO),... Read More
January 11, 2023
iCAD Announces Board of Directors Transition
NASHUA, N.H., Jan. 11, 2023 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced the appointment of Dana Brown as Executive Chair of the Board of Directors. Ms. Brown has been a non-executive board member since February 2022. Prior to joining iCAD’s board, Ms. Brown was the Senior Vice President, Chief Strategy and... Read More
ClearPoint Neuro

COPYRIGHT ©2023 HEALTH STOCKS HUB